Since mutations in another splicesomal gene, SURP and G-patch domain containing 1 (SUGP1), induce aberrant splicing identical or similar to that observed in mutant SF3B1 cancers, it remains to know whether SUGP1 mutations also confer hypersensitivity to Akt inhibitors [256]. The gene discussed is AKT1; the disease is cancer.